B-cell acute lymphoblastic leukemia with MEF2D::BCL9 rearrangement mimicking a Burkitt lymphoma No … ← NG2 at the core: tackling MLLr B-ALL resistance Handa S, Lee J-O, Derkach A, et al. Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy. Blood. 2022;140(25):2663-2671 →